Study Finds 3-Week Radiation Therapy as Effective as 5 Weeks for Early-Stage Breast Cancer

Publication
Article
OncologyONCOLOGY Vol 22 No 11
Volume 22
Issue 11

Early-stage breast cancer patients who receive a more intensive course of radiation to their whole breast over 3 weeks is as effective as the standard, less-intensive 5-week whole-breast radiation and offers patients more convenience at a lower cost, thereby providing a better quality of life, according to a randomized, long-term study presented September 22, 2008, in the plenary session at the 50th Annual Meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO), held in Boston.

Early-stage breast cancer patients who receive a more intensive course of radiation to their whole breast over 3 weeks is as effective as the standard, less-intensive 5-week whole-breast radiation and offers patients more convenience at a lower cost, thereby providing a better quality of life, according to a randomized, long-term study presented September 22, 2008, in the plenary session at the 50th Annual Meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO), held in Boston.

The cost of this shorter treatment, called accelerated hypofractionated whole-breast irradiation, is two-thirds of the cost of the standard whole breast radiation. It is also less expensive then other new approaches such as partial-breast irradiation.

Potential Advantages

“There has been renewed interest in hypofractioned whole-breast irradiation, due to the potential radiation advantages, patient convenience, quality of life, and lower costs. However, long-term effects were a potential concern,” Timothy Whelan, md, lead author of the study and a radiation oncologist at the Juravinski Cancer Centre at McMaster University in Hamilton, Ontario, Canada, said. “We were surprised that the risk of local recurrence and side effects for women treated with accelerated whole-breast irradiation was so low even at 12 years. Our study shows that this treatment should be offered to select women treated with early-stage breast cancer.”

Many women with early-stage breast cancer are able to undergo breast-conserving therapy to keep their breast after treatment. Typically, this means they first have surgery to remove the cancer followed by a course of radiation therapy to kill any cancer cells that may remain. The standard whole-breast radiation therapy treatment takes approximately 15 minutes every day, Monday through Friday, for 5 weeks.

Study Details

Between April 1993 and September 1996, researchers randomly assigned 1,234 women to be treated with either accelerated whole-breast irradiation or standard whole-breast irradiation. These women were followed for 12 years to determine if accelerated whole-breast irradiation was as effective as the standard treatment. At 10 years after treatment, cancer returned locally in 6.2% of patients treated with the accelerated radiation therapy, compared to 6.7% for those patients treated with standard therapy. Both groups of patients also had a good or excellent cosmetic outcome from the radiation treatments.

“This shorter treatment may not be for everyone, however. I would encourage women whose breast cancer is caught early to talk to their oncologist to see if they are a good candidate for this shorter therapy,” Dr. Whelan added.

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.